G. Predictis, S. A. Thierry, and D. , Pache is a Board Member and shareholder of Gene Predictis S.A. and Johannes Bitzer is a Scientific Board Member of Gene Predictis S.A. Patient consent for publication Not required

, Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial

K. E. Hersberger,

J. W. Goldzieher and H. W. Rudel, How the oral contraceptives came to be developed, JAMA, vol.230, pp.421-426, 1974.

J. T. Jensen and L. Speroff, Health benefits of oral contraceptives, Obstet Gynecol Clin North Am, vol.27, pp.705-726, 2000.

. Cadth-optimal-use and . Reports, Effectiveness of factor V Leiden and prothrombin mutation testing in patients presenting with a first unprovoked venous thromboembolic episode: a systematic review and economic analysis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2015.

F. R. Rosendaal, Causes of venous thrombosis, Thromb J, vol.14, p.24, 2016.

J. A. Heit, M. A. Phelps, and S. A. Ward, Familial segregation of venous thromboembolism, J Thromb Haemost, vol.2, pp.731-737, 2004.

F. Fruzzetti, F. Trémollieres, and J. Bitzer, An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest, Gynecol Endocrinol, vol.28, pp.400-408, 2012.

G. Plu-bureau, L. Maitrot-mantelet, and J. Hugon-rodin, Hormonal contraceptives and venous thromboembolism: an epidemiological update, Best Pract Res Clin Endocrinol Metab, vol.27, pp.25-34, 2013.

M. Germain, D. I. Chasman, and H. De-haan, Meta-Analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism, Am J Hum Genet, vol.96, pp.532-574, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01259946

J. L. Kujovich and . Factor-v-leiden-thrombophilia, Genet Med, vol.13, pp.1-16, 2011.

R. Junker, H. G. Koch, and K. Auberger, Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia, Arterioscler Thromb Vasc Biol, vol.19, pp.2568-72, 1999.

J. Hippisley-cox and C. Coupland, Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study, BMJ, vol.343, p.4656, 2011.

G. Merki-feld, J. Bitzer, and J. Seydoux, Avis d'experts No. 35 Risque thromboembolique sous contraception hormonale, 2015.

A. Mcdaid, E. Logette, and V. Buchillier, Risk prediction of developing venous thrombosis in combined oral contraceptive users, PLoS One, vol.12, p.182041, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01606432

Z. Ademi, C. S. Sutherland, V. Stiphout, and J. , A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives, J Thromb Thrombolysis, vol.44, pp.494-506, 2017.

E. Vernon, B. Hiedemann, and B. H. Bowie, Economic evaluations of thrombophilia screening prior to prescribing combined oral contraceptives: a systematic and critical review, Appl Health Econ Health Policy, vol.15, pp.583-95, 2017.

D. Husereau, D. A. Marshall, and A. R. Levy, Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?, Int J Technol Assess Health Care, vol.30, pp.179-87, 2014.

Z. Ademi, A. M. Pfeil, and E. Hancock, Cost-Effectiveness of sacubitril/ valsartan in chronic heart-failure patients with reduced ejection fraction, Swiss Med Wkly, vol.147, p.14533, 2017.

R. Parrott, S. J. Hong, and M. Greenberg, Family history unawareness of blood clot risk: links to misdiagnoses and illness uncertainties in personal and expert realms, J Health Commun, vol.20, pp.35-42, 2015.

M. Firmann, V. Mayor, and P. M. Vidal, The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome, BMC Cardiovasc Disord, vol.8, p.6, 2008.

L. Øjvind, L. H. Nielsen, and C. W. Skovlund, Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, BMJ, vol.343, p.6423, 2011.

M. Johansson, L. Johansson, and M. Lind, Incidence of venous thromboembolism in northern Sweden (veins): a population-based study, Thromb J, vol.12, p.6, 2014.

F. Martínez, I. Ramírez, and E. Pérez-campos, Venous and pulmonary thromboembolism and combined hormonal contraceptives. systematic review and meta-analysis, Eur J Contracept Reprod Health Care, vol.17, pp.7-29, 2012.

M. D. Silverstein, J. A. Heit, and D. N. Mohr, Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study, Arch Intern Med, vol.158, pp.585-93, 1998.

H. T. Sørensen, E. Horvath-puho, and L. Pedersen, Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study, Lancet, vol.370, pp.1773-1782, 2007.

A. Compagni, A. Melegaro, and R. Tarricone, Genetic screening for the predisposition to venous thromboembolism: a cost-utility analysis of clinical practice in the Italian health care system, Value Health, vol.16, pp.909-930, 2013.

C. Laczkovics, H. Grafenhofer, and A. Kaider, Risk of recurrence after a first venous thromboembolic event in young women, Haematologica, vol.92, pp.1201-1208, 2007.

T. V. Perneger, C. Combescure, and D. S. Courvoisier, General population reference values for the French version of the EuroQol EQ-5D health utility instrument, Value Health, vol.13, pp.631-636, 2010.

K. K. Utne, M. Tavoly, and H. S. Wik, Health-Related quality of life after deep vein thrombosis, Springerplus, vol.5, p.1278, 2016.

P. W. Sullivan, J. F. Slejko, and M. J. Sculpher, Catalogue of EQ-5D scores for the United Kingdom, Med Decis Making, vol.31, pp.800-804, 2011.

. Bundesamt-für-statistik and . Konsumentenpreise, , 2018.

S. Bundesamt-fur, SwissDRG-Kodes (patientenbezogene Diagnosegruppen) gemäss Verson 5.0, 2014.

, FMH Swiss Medical Board. TARMED Tarifbrowser 1.08, valid from 1.1.2012, 2018.

. Sfoph and . Spezialtaetenliste, , 2018.

. Apotheken and . Apthekeon, , 2018.

D. Husereau, M. Drummond, and S. Petrou, Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force, Value Health, vol.16, pp.231-50, 2013.

M. Blondon, F. Boehlen, and P. Fontana, Genetic testing to identify women at risk of venous thromboembolism with contraceptive pills: Evidence or hope-based tool, Swiss Med Wkly, vol.146, pp.656-63, 2012.

P. Morange, P. Suchon, and D. Trégouët, Genetics of venous thrombosis: update in 2015, Thromb Haemost, vol.114, pp.910-919, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01479775

C. Rubio-terrés, J. M. Soria, and P. E. Morange, Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism, Appl Health Econ Health Policy, vol.13, pp.233-275, 2015.

S. Mantha, R. Karp, and V. Raghavan, Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis, BMJ, vol.345, p.4944, 2012.

S. Robertson, P. Kremer, and B. Aisbett, Consensus on measurement properties and feasibility of performance tests for the exercise and sport sciences: a Delphi study, Sports Med Open, vol.3, 2017.

G. B. Bundesamt-für and . Analysenliste, , 2018.

M. C. De-visser, S. R. Poort, and H. L. Vos, Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis, Thromb Haemost, vol.85, pp.1011-1018, 2001.